Development Intelligence Platform · Biopharma & CDMOs
See risk before it becomes a delay
BioXion is an AI-powered development intelligence platform for biopharmaceutical companies and CDMOs. It connects Program Development, analytical, quality, regulatory, and supply chain data — and gives leadership the visibility to act before programs fall behind.
From preclinical to post-approval lifecycle — one intelligence platform for biopharma and CDMOs.
The problem
Your program is running blind. Your tools aren’t built to fix that.
Most development delays don't come from science — they come from broken coordination between partners. Program Development data lives in one system, CDMO performance in another, quality events in a third. No team sees the complete picture until the delay is already a fact.
BioXion is built specifically for this problem. It aggregates signals across every development function — Program Development, CDMO, analytical, quality, regulatory, supply chain — and surfaces cross-functional risk before it cascades into a timeline or regulatory consequence. The four failure modes below define what disconnected program intelligence looks like in practice.
01
No one sees the full picture
Program Development, quality, CDMO, and regulatory data live in separate systems. Cross-functional risk is invisible — until it’s already a delay.
02
Decisions are made without context
By the time a signal reaches leadership, it’s already a problem. The window to act has closed.
03
Regulatory gaps appear at inspection
FDA, EMA, and ICH guidance is tracked manually — with no link to active programs. Deficiencies are found at review, not before.
04
You’re managing the past
Every current tool tells you what happened. None of them tell you what’s about to go wrong — and what it will cost your program.
The platform
One intelligence platform. Every development function.
BioXion doesn’t replace your systems — it gives you a unified view across them. It sits above your QMS, LIMS, and ELN as a program-level intelligence platform, structuring information across every function and surfacing what no individual tool can see.
✦AI Insight — under development — is not a module or a chatbot. It is the cross-cutting intelligence layer across Program Development and later modules — turning structured, scored program information into explainable, advisory and editable narratives for management and partners. Every output is traceable and remains subject to expert review.
Under development
⬡
Under development
Program Development
Know where your program stands — at every phase, across every workstream
▾
The Program Development module, accessed through the Program Development Navigator, provides modality-, stage- and market-specific development roadmaps from preclinical through commercial and into Post-Approval & Lifecycle — covering Drug Substance, Drug Product, Analytical, and Regulatory workstreams across 9 modalities. Post-Approval & Lifecycle is treated as a continuous stage rather than a numbered phase, feeding a cross-module Lifecycle Overview. Each step is linked to relevant regulatory context and readiness status.
✦
Under development
Program Intelligence Dashboard
Readiness, risks and milestones — rolled up for leadership.
▾
An executive and program-level roll-up across BioXion — readiness, active milestones, material risks, and AI-supported management narratives based on structured information available within BioXion. Risks ranked by severity, phase, and regulatory impact — each explained in plain language and subject to expert review.
Coming soon
◈
Coming soon
Partner Programs
Track every partner commitment — before it becomes a program risk
▾
Sponsor-side CDMO oversight and CDMO-side client program management — on the same data model. Tracks tech-transfer milestones, manufacturing deliverables, audit findings, and partner risk across every manufacturing site. Linked to Program Development steps and quality events so gaps don't stay invisible until a batch fails.
◎
Coming soon
Analytical Intelligence
Catch method failures before they delay your submission
▾
Full method lifecycle management — development, qualification, validation, and transfer — designed to help teams surface potential method-performance issues for expert review before they enter the formal review cycle.
◉
Coming soon
Quality Intelligence
Connect quality events to the programs they affect
▾
Deviations, CAPAs, change controls, and audit readiness — each linked to the Program Development step and CDMO activity it may affect. BioXion is designed to connect quality signals with the program activities, milestones and risks they may affect.
On the roadmap
⬖
On the roadmap
Regulatory Intelligence
Know your submission gaps before the agency finds them
▾
Submission portfolio management across FDA, EMA, ICH, and Swissmedic — with structured readiness scoring and monitoring of selected guidance sources, with potentially relevant changes surfaced against your active programs for expert review.
⬡
On the roadmap
Supply Chain Intelligence
Surface supply risk before it disrupts your clinical timeline
▾
Structured visibility into material availability, CDMO capacity, and cold-chain considerations — linked to active manufacturing campaigns and clinical milestones.
✦
Also from Helvetia Tech Solutions
BioXion covers the program. FormulytiX covers the molecule.
FormulytiX is a separate formulation-intelligence platform being developed by Helvetia Tech Solutions. Where BioXion manages your development program, FormulytiX focuses on drug product formulation.
The Program Intelligence Dashboard gives leadership a connected view of program readiness, active milestones, material risks and relevant regulatory signals — based on structured information available within BioXion.
Program Intelligence Dashboard
Readiness · Open risks · Active milestones · Regulatory signals
✦ AI-powered
Built for decision makers
For the leaders who can’t afford to be the last to know
◎
Portfolio visibility
Every program. Every function. Every site. One view — kept current from structured program information, without chasing status reports.
◈
Readiness scoring
A single number that reflects where your program actually stands — calculated from structured program information, not PowerPoint slides.
✦
Strategic signals
Risk surfaced before it becomes delay. Regulatory gaps flagged before inspection. Decisions made on facts, not instinct.
⬡
BioXion doesn’t replace your systems — it gives you a unified view across them.
Users reference their program documents directly within BioXion, which structures and connects that information — giving leadership a connected intelligence picture without touching your existing infrastructure.
Use cases
Where BioXion delivers impact
Program Development Planning
BioXion provides development teams with an AI-generated Program Development plan that adapts to therapeutic modality, development phase, and regulatory target. Instead of building roadmaps manually from guidance documents, teams get a structured, phase-appropriate plan with regulatory context embedded at every step — reducing the risk of missing critical Program Development milestones before IND or BLA submission.
Partner Programs
Managing contract manufacturing partnerships is one of the highest-risk activities in drug development — for sponsors and CDMOs alike. BioXion is designed to consolidate partner oversight into a single intelligence view, tracking tech-transfer milestones, manufacturing deliverables, audit findings, and partner risk in one structured view. Program coordination becomes proactive, not reactive. Partner Programs is planned for v2.0.
GMP Readiness & Risk Monitoring
GMP readiness failures are rarely sudden — they are the result of signals that were present but not connected. BioXion is designed to connect quality events, deviation patterns, and CDMO performance data to help surface GMP readiness risks for expert review before they escalate. This AI platform for drug development is intended to give quality and operations teams earlier warning to act. Quality Intelligence is planned for v2.0.
Cross-Functional Intelligence
In complex development programs, a regulatory gap can delay a manufacturing campaign; a partner issue can trigger a quality event; a Program Development deviation can affect submission readiness. BioXion connects structured information across development functions to help leadership understand potential cross-functional impact — a connected view of program risk that no individual system or team can produce alone.
Knowledge base
Explore BioXion Intelligence Modules
Each module in the BioXion platform addresses a distinct Program Development function. Below is the knowledge base — built from 15+ years of biopharma and CDMO industry experience and the same domain logic that powers the platform.
No — intentionally. BioXion is a non-GxP program intelligence platform. It operates above your validated infrastructure, structuring and linking key program information without touching your QMS, LIMS, or ELN. It is a non-GxP decision-support layer, not the system of record for regulated GMP data; customer validation expectations depend on intended use.
No. BioXion doesn’t compete with your QMS, LIMS, or ELN — it gives you a unified view across them. Think of it as the intelligence platform that sits above your existing stack and surfaces what those systems can’t show you individually.
BioXion v1.0 uses structured data entry and file import where supported, without a mandatory customer IT-integration project for initial deployment. A documented REST API and selected supported connectors to prioritised eQMS, LIMS and project-management systems are planned from v2.0.
Users enter and structure program information directly within BioXion and may import supported structured files or reference documents held in existing customer systems. There is no mandatory customer IT-integration project for initial deployment.
Early access partners are onboarded in a structured process designed to deliver first program visibility quickly. Onboarding timelines are an early-access design target rather than a guaranteed service level. We work directly with your team to configure the platform around your program structure and existing data.
Data is hosted in Switzerland with Swiss data residency, deployed in Azure Switzerland North with tenant-isolated hosting. Access to external AI services is controlled where applicable, and customer-specific security and AI-processing requirements can be agreed contractually. Entity masking is designed to reduce exposure of customer-identifying information before selected external AI processing.
9 modalities: Small Molecule, mAb, ADC, mRNA, Recombinant Protein, Viral Vector Vaccine, Cell Therapy, Gene Therapy, and Oligonucleotide — plus Custom Modality. Each has modality-specific regulatory logic and Program Development structure built in.
No. BioXion is designed to support programs from Preclinical through Commercial — and to remain the intelligence backbone through Phase III, post-approval changes, and product lifecycle management.
BioXion is built for Program Development Directors, Heads of Development, Regulatory Affairs leads, and program managers at biopharmaceutical companies and CDMOs — typically those managing complex development programs across multiple partners and regulatory markets where cross-functional visibility is critical.
Early access is by application. We're onboarding a selected group of partners who will help shape the product. Schedule a call using the form below, or reach out directly at [email protected] — and we'll follow up within 48 hours.
Early Access
Your next program delay is already visible — if you know where to look.
BioXion gives your leadership team the visibility to act before programs fall behind. We’re onboarding a selected group of early access partners. Let’s see what your program data reveals.
No commitment required
30-minute intro call
Direct access to the founding team
Schedule a callvia Microsoft Bookings
Pick a slot that works for you
30-minute intro call with the founding team. No commitment — bring your questions, share your context, and we'll show you how BioXion fits your program reality.
